Clinical Trial Update: BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) [Phase 2]

View source ↗

Summary

Phase 2 study of zanubrutinib (BGB-3111) in Chinese participants with Diffuse Large B-Cell Lymphoma (non-GCB) and indolent lymphomas (Follicular Lymphoma and Ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)

Snippet

Sponsor: BeiGene | Conditions: Marginal Zone Lymphoma, Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-10-28